<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525213</url>
  </required_header>
  <id_info>
    <org_study_id>2006-004834-33</org_study_id>
    <nct_id>NCT00525213</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Methotrexate</brief_title>
  <acronym>ROBUST</acronym>
  <official_title>A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Stable Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OxyPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OxyPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy (ACR20) of Rob 803
      administered orally once daily for 12 weeks in combination with a stable dose of methotrexate
      in subjects with moderate or severe active RA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid arthritis (RA) is a common, chronic, disabling systemic autoimmune disease in
      which inflammation of the joint lining (synovium) occurs when the body's tissues are attacked
      by the immune system. The joint inflammation begins in the synovium and slowly destroys the
      cartilage, narrowing the joint and eventually damaging the bone. A large amount of
      inflammatory mediators or rheumatoid factors are synthesised in the joint which accelerate
      proliferation and differentiation of immune cells further to amplify the autoimmune reaction.
      A widely accepted model has emerged in which the presence of inflammation in established RA
      is driven by interactions between T cells, macrophages, and fibroblasts in an abnormal
      microenvironment.

      Rheumatoid arthritis has an annual incidence of approximately 0.2 per 1000 in males and 0.4
      per 1000 in females. In general, higher rates have been reported in the USA than in European
      populations. The incidence of RA increases with age until the mid 70s. A prevalence of 0.5-1%
      is reported in diverse populations world-wide.

      Treatments for RA focus on relieving pain, reducing inflammation, slowing or stopping joint
      damage, and improving patients' well being and ability to function. Current therapies include
      non-steroidal anti-inflammatory drugs (NSAIDs) which target the clinical features of the
      disease to alleviate the pain and swelling that accompany RA, disease-modifying
      anti-rheumatic drugs (DMARDs) which target the actual cause of the disease and biological
      agents which are genetically engineered to target and modify the autoimmune response.
      Non-steroidal anti-inflammatory drugs are effective in managing the symptoms of RA, but are
      limiting as they cannot suppress progression of the disease. First line treatment on
      confirmation of RA is the use of DMARDs, supported by pain relief medication.

      Biologic agents (TNF antagonists, anti B-cell agents and anti-interleukins) have proven
      effective in RA symptoms management. TNF antagonists have become an important therapeutic
      option in the treatment of advanced RA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy (ACR20) of Rob 803 administered orally once daily for 12 weeks in combination with a stable dose of methotrexate in subjects with moderate or severe active RA.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety of Rob 803 administered orally once daily in combination with a stable dose of methotrexate in subjects with moderate or severe active RA</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rob 803</intervention_name>
    <description>two capsules per day during 12 weeks</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>two capsules per day during 12 weeks</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with RA based on the ARA 1987 revised criteria at least 16 weeks prior to
             study enrolment, Day 0

          -  Have an ACR global functional status class of 1 to 3

          -  Have active disease, defined as the presence of 6 swollen joints and 6 tender joints
             in a 44 joint examination

          -  Have a CRP level at screening of ≥ 1.5 mg/dL

          -  Have been taking oral or parenteral methotrexate (15 mg weekly or above), have been
             using methotrexate for at least 16 weeks (up to Day 0 of study), and have been on a
             stable dose for at least 8 weeks, up to Day 0.

        Exclusion Criteria:

          -  Arthritis onset prior to 16 years old

          -  Any of the following infections:

          -  Known or acute infection that may affect CRP levels

          -  Active tuberculosis

          -  Known chronic infection with human immunodeficiency virus (HIV), hepatitis C virus
             (HCV) or hepatitis B virus (HBV) including positive serology

          -  Ongoing systemic inflammatory condition which may interfere with the results of
             clinical or laboratory tests planned in the study (eg, systemic lupus erythematosus or
             any other systemic rheumatic disease other than RA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Klareskog, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CUB Hôpital Erasme Université Libre de Bruxelles Service de Rhumatologie</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas Gent Reumatologie</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumainstituut Anne Frankplein 17</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Cardiology and Rheumatology UMHAT &quot;Dr. Georgi Stranski&quot;</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT sveti georgi</name>
      <address>
        <city>Ploviv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Rheumatology MHAT &quot;Sveti Ivan Rilski&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumocardiology, Pulmonology and General Therapy</name>
      <address>
        <city>Sofia</city>
        <zip>1874</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Rheumatology, UMHAT &quot;Sveta Marina&quot;,</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academician V Tsitlanadze Scientific-Practical Centre of Rheumatolgoy</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department Cemotherapy and Immunotherapy Clinical</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D Saulites-Kandevicas gimenes arsta prakse</name>
      <address>
        <city>Liepaja</city>
        <state>Aldaru iela 8,</state>
        <zip>LV 3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salenieces arsta reimatologa prakse</name>
      <address>
        <city>Valmiera</city>
        <zip>LV4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Clinic Hospital of Kaunas University of Medicine</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Therapy and diagnostics Siauliai district hospital</name>
      <address>
        <city>Siauliai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Reumathology Vilnius University hospital Santariskiu Clinics</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Miriada Prywatny Gabinet</name>
      <address>
        <city>Bialystok</city>
        <zip>Zelazna 9, lok.13U</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny Nr 1 Oddzial Reumatologii i Rehabilitacji</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poznanski Osrodek Medyczny Nova Med</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Osteomed</name>
      <address>
        <city>Warszawa</city>
        <zip>02-256</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Sf. Maria&quot; Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Dr. I. Cantacuzino&quot; Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Clinical County Hospital</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Dr. Constantin Papilian&quot;</name>
      <address>
        <city>Cluj-Napoca,</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Clinical Hospital</name>
      <address>
        <city>Lasi</city>
        <zip>700662</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Hospital</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology Belgrade</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Prevention, Treatment and Rehabilitation of Rheumatic and Cardiovascular Diseases</name>
      <address>
        <city>Niska Banja</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologiska kliniken Karolinska Sjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musculo Skeletal dept Chapel Allerton Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vectasearch Clinic Ltd St Mary's Hospital</name>
      <address>
        <city>Newport</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Unit North Tyneside District General Hospital</name>
      <address>
        <city>North Shields</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <last_update_submitted>August 20, 2009</last_update_submitted>
  <last_update_submitted_qc>August 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ulf Björklund</name_title>
    <organization>OxyPharma AB</organization>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

